CYDYOTCPharmaceutical PreparationsFiscal year ends May 31

CytoDyn Inc.

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 14, 2026

$0.25+0.02 (+9.53%)

Close on Oct 19, 2026

Market cap: $345.56M
P/E (TTM): –
Dividend yield: –

CytoDyn Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-05-31	FY 2025 2025-05-31	FY 2024 2024-05-31	FY 2023 2023-05-31	FY 2022 2022-05-31	FY 2021 2021-05-31	FY 2020 2020-05-31	FY 2019 2019-05-31	FY 2018 2018-05-31	FY 2017 2017-05-31	FY 2016 2016-05-31	FY 2015 2015-05-31	FY 2014 2014-05-31	FY 2013 2013-05-31	FY 2012 2012-05-31	FY 2011 2011-05-31	FY 2010 2010-05-31	FY 2009 2009-05-31	FY 2008 2008-05-31	FY 2007 2007-05-31
Revenue	–	–	–	0	0.27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Cost of Revenue	–	–	–	–	0.05	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	–	–	–	–	0.21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	–	–	7.24	2.63	27	53	53	42	38	20	14	15	3.98	0.62	0.53	0.48	–	–	–	–
General & Administrative	7.45	7.26	11	17	44	34	20	12	7.34	6.76	7.08	3.29	3.11	6.20	5.45	2.53	–	–	–	–
Operating Expenses	–	–	–	–	–	–	75	56	46	27	21	20	8.11	7.99	7.46	3.70	–	–	–	–
Total Costs & Expenses	39	-9.66	18	41	146	105	75	56	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-39	9.66	-18	-41	-145	-105	-75	-56	-46	-27	-21	-20	-8.11	-7.99	-7.46	-3.70	–	–	–	–
Interest Expense	–	–	–	–	–	–	18	3.31	5.92	0.61	4.67	4.66	4.51	1.95	–	–	–	–	–	–
Interest & Investment Income	0.26	0.57	0.22	–	–	0.00	0.01	0.00	0.00	0.02	0.01	0.00	0.01	0.00	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	0.00	–	–	0.00	–	–	–	–	–
Legal Settlements	–	–	–	–	–	-11	-23	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-43	3.75	-50	-80	-211	-176	-140	-64	-50	-26	-26	-25	-12	-9.57	-7.47	-3.72	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	-2.83	0	0	0	0	0	–	–	–	–	–	–	–
Net Income	-43	3.75	-50	-80	-211	-176	-140	-61	-50	-26	-26	-25	-12	-9.57	-7.47	-3.72	-3.36	-1.31	-1.19	-2.61
Preferred Dividends	–	–	–	1.33	1.33	1.91	0.95	0.04	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-44	2.26	-51	-87	-212	-178	-141	–	–	–	–	–	-12	-9.57	-7.56	-3.73	–	–	–	–
EPS (Basic)(per share)	-0.03	0.00	-0.05	-0.10	-0.31	-0.30	-0.33	-0.23	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Diluted)(per share)	-0.03	0.00	-0.05	-0.10	-0.31	-0.30	-0.33	-0.23	–	–	–	–	–	–	–	–	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	1,289	1,206	970	837	677	588	421	272	175	138	95	58	47	30	25	21	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	1,289	1,243	970	837	677	588	421	272	175	138	95	58	47	30	25	21	–	–	–	–
EBITDA	-39	9.68	-18	-40	-145	-103	-73	-55	-46	-27	-21	-19	-7.76	-7.77	-7.45	-3.70	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Aug 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: 41.5%

Financial strength

Current ratio: 0.38
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 32.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –